Bristol-Myers Squibb, CHECKMATE-76K, FDA, melanoma, Abin al'ajabi
Nivolumab an amince da ita ta FDA don maganin adjuvant na Stage IIB/C melanoma
Nov 2023: Nivolumab (Opdivo, Kamfanin Bristol-Myers Squibb) ya sami izini daga Hukumar Abinci da Magunguna a matsayin magani mai ba da taimako ga Stage IIB/C melanoma a cikin marasa lafiya masu shekaru 12 da haihuwa waɗanda suka sami cikakkiyar lafiya.
BMS, Bristol Myers Squibb, immunotherapy, metastatic melanoma, nivolumab da relatlimab, nivolumab da relatlimab-rmbw, Opdualag, USFDA
Farkon LAG-3-Tsarin hanawar rigakafin jiki, Opdualag ™ (nivolumab da relatlimab-rmbw), FDA ta amince da su ga marasa lafiya da ke da melanoma da ba a sake su ba.
Afrilu 2022: Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da Opdualag (nivolumab da relatlimab-rmbw), sabon, ƙayyadaddun ƙayyadaddun adadin kashi na farko na nivolumab da relatlimab waɗanda ake gudanarwa azaman jiko guda ɗaya, f..
Immunocore Limited girma, Kimmtrak, metastatic uveal melanoma, tebentafusp-tebn, ciwon daji na melanoma
An amince da Tebentafusp-tebn don rashin gyarawa ko kuma melanoma mai tsauri
Maris 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), bispecific gp100 peptide-HLA-directed CD3 T cell engaged, an ba shi lasisi daga Hukumar Abinci da Magunguna don HLA-A * 02: 01-tabbatattun marasa lafiya marasa lafiya tare da unresectab. .
CD-38, FDA, Sararin sama, immunomodulatory wakili, melphalan flufenamide, Multi myeloma, NCT02963493, Oncopeptides AB girma, Pepaxto
Melphalan flufenamide yana samun amincewa daga FDA don sake komawa ko rage yawan myeloma
Agusta 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) a haɗe tare da dexamethasone an ba da izinin haɓaka ta Hukumar Abinci da Magunguna ga marasa lafiya marasa lafiya da suka sake komawa ko suka ƙi wartsakewa.
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, KARANTA, USFDA
Pembrolizumab ya amince da FDA don adjuvant magani na melanoma
A ranar 15 ga Fabrairu, 2019, Hukumar Abinci da Magunguna ta amince da pembrolizumab (KEYTRUDA, Merck) don kula da marasa lafiya tare da melanoma tare da shigar da kumburin lymph bayan cikakken resection. Amincin ya..
Jirgin bariatric, Delhi, India, Amurka
Yin tiyatar ciki na iya rage haɗarin cutar melanoma
Baya ga saurin nauyi mai dorewa da kuma sauran amfani na kiwon lafiya, aikin tiyatar bariatric yanzu yana da nasaba da kasada 61% na kasadar kamuwa da cutar melanoma, wanda shine mafi yawan cututtukan daji na fata mafi kusanci da alaƙa da s ..